Compare Stocks: BHC, LNTH, AMRX, and BLTE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$19.74 +0.4%	$18.42	$9.56 ▼ $21.17	$6.31B	1.22	2.23 million shs	211,339 shs
BHC Bausch Health Cos	$6.07 +0.4%	$6.21	$4.33 ▼ $8.00	$2.27B	0.37	2.49 million shs	192,635 shs
BLTE Belite Bio	$153.81 +0.8%	$166.42	$77.64 ▼ $200.00	$6.19B	-1.23	191,470 shs	45,737 shs
LNTH Lantheus	$100.35 +0.2%	$100.48	$50.15 ▼ $111.86	$6.55B	-0.06	1.08 million shs	378,132 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	0.00%	-2.09%	+15.25%	+15.52%	+87.50%
BHC Bausch Health Cos	-1.79%	+5.59%	-6.06%	+26.60%	-4.95%
BLTE Belite Bio	-2.28%	-6.42%	-20.91%	+2.14%	+95.39%
LNTH Lantheus	-0.06%	+0.47%	-0.32%	-5.23%	+86.97%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$19.74 +0.4%	$18.42	$9.56 ▼ $21.17	$6.31B	1.22	2.23 million shs	211,339 shs
BHC Bausch Health Cos	$6.07 +0.4%	$6.21	$4.33 ▼ $8.00	$2.27B	0.37	2.49 million shs	192,635 shs
BLTE Belite Bio	$153.81 +0.8%	$166.42	$77.64 ▼ $200.00	$6.19B	-1.23	191,470 shs	45,737 shs
LNTH Lantheus	$100.35 +0.2%	$100.48	$50.15 ▼ $111.86	$6.55B	-0.06	1.08 million shs	378,132 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	0.00%	-2.09%	+15.25%	+15.52%	+87.50%
BHC Bausch Health Cos	-1.79%	+5.59%	-6.06%	+26.60%	-4.95%
BLTE Belite Bio	-2.28%	-6.42%	-20.91%	+2.14%	+95.39%
LNTH Lantheus	-0.06%	+0.47%	-0.32%	-5.23%	+86.97%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRX Amneal Pharmaceuticals	2.80	Moderate Buy	$21.00	6.41% Upside
BHC Bausch Health Cos	2.14	Hold	$8.00	31.90% Upside
BLTE Belite Bio	2.64	Moderate Buy	$218.73	42.21% Upside
LNTH Lantheus	2.29	Hold	$108.11	7.74% Upside

Current Analyst Ratings Breakdown

Latest BHC, LNTH, AMRX, and BLTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	BHC Bausch Health Cos	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sector Perform	$9.00
10/6/2026	AMRX Amneal Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
10/2/2026	BLTE Belite Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/1/2026	AMRX Amneal Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/25/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
9/23/2026	AMRX Amneal Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$27.00
9/21/2026	BHC Bausch Health Cos	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
9/17/2026	AMRX Amneal Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$16.00 ➝ $20.00
9/10/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
9/9/2026	BLTE Belite Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$220.00 ➝ $234.00
9/9/2026	BLTE Belite Bio	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold

(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRX Amneal Pharmaceuticals	$3.12B	2.02	$1.57 per share	12.58	($0.23) per share	-85.80
BHC Bausch Health Cos	$10.85B	0.21	$7.22 per share	0.84	$1.02 per share	5.95
BLTE Belite Bio	N/A	N/A	N/A	N/A	$20.54 per share	N/A
LNTH Lantheus	$1.54B	4.25	$6.40 per share	15.69	$16.43 per share	6.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRX Amneal Pharmaceuticals	$72.06M	$0.49	40.30	18.27	2.31	5.05%	-584.46%	7.78%	N/A
BHC Bausch Health Cos	$157M	-$2.96	N/A	1.51	N/A	-10.12%	-561.95%	6.31%	10/28/2026 (Estimated)
BLTE Belite Bio	-$77.61M	-$2.73	N/A	169.02	N/A	N/A	-11.84%	-11.62%	11/9/2026 (Estimated)
LNTH Lantheus	$233.56M	$4.14	24.23	17.89	N/A	17.69%	28.10%	14.35%	11/5/2026 (Estimated)

Latest BHC, LNTH, AMRX, and BLTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	LNTH Lantheus	$1.26	N/A	N/A	N/A	$360.82 million	N/A
10/28/2026	Q3 2026	BHC Bausch Health Cos	$1.24	N/A	N/A	N/A	$2.72 billion	N/A
8/12/2026	Q2 2026	BLTE Belite Bio	-$0.73	-$0.54	+$0.19	-$0.70	N/A	N/A
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
7/30/2026	Q2 2026	AMRX Amneal Pharmaceuticals	$0.24	$0.30	+$0.06	$0.18	N/A	$796.20 million
7/29/2026	Q2 2026	BHC Bausch Health Cos	$0.96	$1.26	+$0.30	$0.68	$2.59 billion	$2.83 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRX Amneal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRX Amneal Pharmaceuticals	77.65	2.20	1.44
BHC Bausch Health Cos	N/A	1.44	1.08
BLTE Belite Bio	N/A	33.56	33.56
LNTH Lantheus	0.43	3.06	2.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRX Amneal Pharmaceuticals	31.82%
BHC Bausch Health Cos	78.65%
BLTE Belite Bio	0.53%
LNTH Lantheus	99.06%

Insider Ownership

Company	Insider Ownership
AMRX Amneal Pharmaceuticals	17.30%
BHC Bausch Health Cos	20.67%
BLTE Belite Bio	13.29%
LNTH Lantheus	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRX Amneal Pharmaceuticals	8,500	319.35 million	264.11 million	Optionable
BHC Bausch Health Cos	20,300	374.38 million	297.00 million	Optionable
BLTE Belite Bio	41	40.27 million	34.92 million	Not Optionable
LNTH Lantheus	1,193	65.27 million	64.16 million	Optionable

BHC, LNTH, AMRX, and BLTE Headlines

Recent News About These Companies

Lantheus (NASDAQ:LNTH) Stock Price Crosses Below 50-Day Moving Average - Time to Sell?

October 9 at 3:59 AM | marketbeat.com

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Option Care Health, Inc. (Nasdaq – OPCH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX), Sangoma Technologies Corporation (Nasdaq – SANG)

October 6 at 10:25 AM | globenewswire.com

Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Rated “Hold” by Wall Street Analysts

October 1, 2026 | defenseworld.netD

Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Has Consensus Target Price of $108.11 According to Analysts

October 1, 2026 | americanbankingnews.com

Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Rated "Hold" by Wall Street Analysts

October 1, 2026 | marketbeat.com

Lantheus Holdings, Inc. Receives Cms Transitional Pass-Through Status and Permanent Hcpcs Code for Pylarify Truvu

September 30, 2026 | marketscreener.comM

Lantheus Holdings, Inc. erhält CMS-Status für vorübergehende separate Erstattung und dauerhaften HCPCS-Code für Pylarify TruVu

September 30, 2026 | de.marketscreener.comD

Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)

September 30, 2026 | globenewswire.com

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SoundThinking, Inc. (Nasdaq – SSTI), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX), Sangoma Technologies Corporation (Nasdaq – SANG)

September 29, 2026 | globenewswire.com

Lantheus Holdings, Inc. Announces First Patient Dosed In SPARROW Phase 2/3 Registrational Trial Evaluating LNTH-2401 In Prostate Cancer

September 28, 2026 | marketscreener.comM

Lantheus Holdings, Inc.: Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer

September 28, 2026 | finanznachrichten.de

Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer

September 28, 2026 | globenewswire.com

Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval

September 26, 2026 | finance.yahoo.com

Lantheus Holdings (LNTH) Stock May Be 14% Undervalued On FDA Approval

September 25, 2026 | finance.yahoo.com

Lantheus (NASDAQ:LNTH) Stock Price Breaks Below Fifty Day Moving Average - Here's What Happened

September 25, 2026 | marketbeat.com

FDA approval for Lantheus’ Bravnetsa

September 24, 2026 | thepharmaletter.comT

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX)

September 24, 2026 | globenewswire.com

3 Reasons LNTH is Risky and 1 Stock to Buy Instead

September 23, 2026 | finance.yahoo.com

Lantheus Holdings, Inc. Receives Final FDA Approval for BRAVNETSA for Treatment of GEP-NETs

September 22, 2026 | marketscreener.comM

FDA approves Lantheus' Bravnetsa as equivalent to Lutathera for GEP-NETs

September 22, 2026 | streetinsider.com

Lantheus Holdings stock faces a new Curium review window

September 22, 2026 | ad-hoc-news.deA

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC, LNTH, AMRX, and BLTE Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

$19.74 +0.09 (+0.43%)

As of 11:54 AM Eastern

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Bausch Health Cos NYSE:BHC

$6.06 +0.03 (+0.41%)

As of 11:53 AM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Belite Bio NASDAQ:BLTE

$153.81 +1.29 (+0.84%)

As of 11:53 AM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Lantheus NASDAQ:LNTH

$100.34 +0.23 (+0.22%)

As of 11:54 AM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BHC, LNTH, AMRX, and BLTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BHC, LNTH, AMRX, and BLTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BHC, LNTH, AMRX, and BLTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC, LNTH, AMRX, and BLTE Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Bausch Health Cos NYSE:BHC

Belite Bio NASDAQ:BLTE

Lantheus NASDAQ:LNTH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BHC, LNTH, AMRX, and BLTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BHC, LNTH, AMRX, and BLTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BHC, LNTH, AMRX, and BLTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC, LNTH, AMRX, and BLTE Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Bausch Health Cos NYSE:BHC

Belite Bio NASDAQ:BLTE

Lantheus NASDAQ:LNTH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools